CBG could reduce the expression of EGFR and CDK2 activity in human liver cancer cells, thereby inhibiting the growth of tumor cells, and enhancing the inhibitory effect of CBG on the proliferation potential of human liver cancer cells. Here, EGFR is linked to liver cancer.